Primary Brain and Central Nervous System Neoplasms in the Automated Central Tumor Registry: 2000-2010 (P07.108)

Objective: Compare the descriptive epidemiology of primary CNS neoplasms in the ACTUR with the Central Brain Tumor Registry of the United States (CBTRUS). Background The Automated Central Tumor Registry (ACTUR) compiles cancer data on Department of Defense beneficiaries (active duty servicemembers (SMs), family members, military retirees). Epidemiologic characteristics of primary CNS neoplasms in this population have not been described previously. Design/Methods: We obtained anatomic location and histologies of malignant and benign primary CNS neoplasms, 2000-2010. Unadjusted incidence rates for active duty SMs were based on the average active duty population, 2000-2009. Overall survival (OS) was estimated by the Kaplan-Meier method. Results: 3452 cases were identified in the ACTUR, 1443 malignant and 2009 benign CNS neoplasms. Overall, median age was 41 years and 53% were male. 8% were ages 0-17, 23% 18-30, 34% 31-49, and 35% over 50. Overall, the most common anatomic locations were pituitary (22.6%), meninges (18.3%), and frontal lobes (11.2%). The most common histologies, including benign and malignant cases, were pituitary (22.4%), meningioma (20.1%) and glioblastoma (12.2%). Median OS for glioblastoma cases diagnosed 2000-2004 (n=207) was 9.9 months versus 12.2 months for cases diagnosed 2005-2010 (n=243), a non-significant difference (p=0.46). 1171 (34%) cases were active duty SMs, 74% were male, median age was 31. In SMs, the most common histologies were pituitary (24.1%), astrocytoma (15.5%) and nerve sheath tumor (11.0%). The unadjusted incidence rate of primary CNS neoplasms in SMs was 8.5 per 100,000, similar to ages 20-34 in the CBTRUS (7.9 per 100,000). Conclusions: Primary CNS neoplasms in DOD beneficiaries have a similar anatomic and histologic breakdown compared to the general U.S. population. Histologic breakdown and incidence rate of cases in active duty SMs were similar to young adults in the CBTRUS. However, despite reports from other registries, OS in glioblastoma cases from the ACTUR did not significantly improve from 2000-2010. Supported by: Disclaimer: The views expressed are those of the author(s) and do not reflect the official policy of the Department of the Army, the Department of Defense or the U.S. Government. Disclosure: Dr. Theeler has nothing to disclose. Dr. Gilbert has received personal compensation for activities with Schering-Plough Corporation and UCB Pharma as speaker and/or consultant. Dr. Gilbert has received research support from Schering-Plough Corporation. Dr. Bondy has nothing to disclose.